Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01207492 · ClinicalTrials.gov registry record · Phase 2

Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor

A Phase 2 study of Tenosynovial Giant Cell Tumor and Pigmented Villonodular Synovitis, sponsored by Andrew J. Wagner, MD, PhD.

Completed
Registry status
Phase 2
Development phase
17
Enrollment target
7
Study locations

NCT01207492 is a Phase 2 study of Tenosynovial Giant Cell Tumor and Pigmented Villonodular Synovitis that has completed, run by Andrew J. Wagner, MD, PhD. The registered enrollment target is 17 participants, below the 116-participant average among 8 other Tenosynovial Giant Cell Tumor trials with a reported enrollment target (85% lower). The trial reports 7 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01207492, a Phase 2 study of Tenosynovial Giant Cell Tumor and Pigmented Villonodular Synovitis, has completed, sponsored by Andrew J. Wagner, MD, PhD.

COMPLETED
Registry status
Phase 2
Development phase
17 participants
Enrollment target
7
Study locations

Study Summary

Nilotinib is a drug that is used to treat a form of a blood cancer called leukemia. Nilotinib works by blocking the action of a protein that might be important for the growth of pigmented villonodular synovitis (PVNS). In this research study the investigators are testing whether nilotinib can stop the growth of PVNS or improve the symptoms experienced from PVNS.

Conditions Studied

Tenosynovial Giant Cell Tumor Pigmented Villonodular Synovitis Diffuse-type Giant Cell Tumor

Interventions

  • DRUG nilotinib

Study Locations (7)

California

  • Sarcoma Oncology Center - Santa Monica
  • Stanford University Medical Center - Stanford

Massachusetts

  • Massachusetts General Hospital - Boston
  • Dana-Farber Cancer Institute - Boston

Florida

  • H. Lee Moffitt Cancer Center - Tampa

Pennsylvania

  • Fox Chase Cancer Center - Philadelphia

Texas

  • UT MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2010-09
Est. Completion 2015-08
Phase Phase 2

Sponsor

Andrew J. Wagner, MD, PhD

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01207492

The ClinicalTrials.gov registry entry for NCT01207492 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 8 other Tenosynovial Giant Cell Tumor trials with a reported enrollment target (85% lower). The listed sponsor is Andrew J. Wagner, MD, PhD, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Tenosynovial Giant Cell Tumor appearing as the primary indexed condition, and to 1 intervention - of which nilotinib is the first listed.

NCT01207492 reports 7 study locations spanning 5 distinct geographic areas - top geographies include California, Massachusetts, Florida.

Frequently Asked Questions

What is clinical trial NCT01207492 about?

NCT01207492 is a clinical study titled "Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor". Nilotinib is a drug that is used to treat a form of a blood cancer called leukemia. Nilotinib works by blocking the action of a protein that might be important for the growth of pigmented villonodular synovitis (PVNS). In this research study the investigators are testing whether nilotinib can stop t...

What is the current status of trial NCT01207492?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2010-09. Estimated completion is 2015-08.

What conditions does trial NCT01207492 study?

This clinical trial studies the following conditions: Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Diffuse-type Giant Cell Tumor.

What interventions are being tested in trial NCT01207492?

The interventions under investigation include: nilotinib (DRUG).

Who is sponsoring clinical trial NCT01207492?

This trial is sponsored by Andrew J. Wagner, MD, PhD, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01207492 being conducted?

This trial has 7 study locations across California, Florida, Massachusetts, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Tenosynovial Giant Cell Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Tenosynovial Giant Cell Tumor

All registered trials for this condition

Pigmented Villonodular Synovitis

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.